Respiratory Syncytial Virus: Vaccination

Department of Health and Social Care written question – answered at on 5 April 2024.

Alert me about debates like this

Photo of Baroness Ritchie of Downpatrick Baroness Ritchie of Downpatrick Non-affiliated

To ask His Majesty's Government how they plan to assess the impact of new immunisation programmes for infant respiratory syncytial virus on (1) hospitalisations, and (2) health inequality.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

The UK Health Security Agency (UKHSA) monitors national immunisation programmes in England. The UKHSA’s Severe Acute Respiratory Infection Watch surveillance system collects weekly information on admissions to hospital with Respiratory Syncytial Virus (RSV), to monitor admission rates in each RSV season. If a programme is introduced, monitoring of its effectiveness would include thorough analysis of immunisation records, both infant or maternal, and laboratory results for patients needing healthcare for RSV-like illness. The UKHSA can also monitor RSV admissions by deprivation and ethnicity, using routine National Health Service records, when these become available following the RSV season. The UKHSA will also monitor inequalities in uptake of the RSV immunisation programmes, through its routine uptake data collections.

Does this answer the above question?

Yes1 person thinks so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.